TPS Monitoring in Metastatic Breast Cancer

1999 ◽  
Vol 14 (1) ◽  
pp. 45-48 ◽  
Author(s):  
A. Van Dalen
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lead Time ◽  
Metastatic Breast ◽  
Hormonal Treatment ◽  
Breast Cancer Patients ◽  
Favorable Prognosis ◽  
Heterogeneous Nature ◽  
Advanced Stages ◽  
Predict Disease Progression

The management of metastatic breast cancer patients reflects the heterogeneous nature of the disease. While patients may benefit from hormonal treatment, in most cases more toxic chemotherapy is applied in the advanced stages. The pretreatment levels of TPS in patients with metastatic breast cancer are correlated with prognosis. Decreasing TPS levels (>50%) during treatment are indicative of response. The fastest decrease in TPS levels is obtained in patients with a favorable prognosis. Increasing TPS levels (>25%) predict disease progression with a considerable lead time (median 8 months). The clinical impact of these observations is discussed in this paper.

The Prognostic Significance of Increasing Marker Levels in Metastatic Breast Cancer Patients with Clinically Complete Remission, Partial Remission or Stable Disease

1998 ◽  
Vol 13 (1) ◽  
pp. 10-15 ◽  
Author(s):  
A. Van Dalen ◽  
V. Barak ◽  
A. Cremaschi ◽  
M. Gion ◽  
R. Molina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Complete Remission ◽  
Cancer Patients ◽  
Stable Disease ◽  
Partial Remission ◽  
Lead Time ◽  
Metastatic Breast ◽  
Breast Cancer Patients

TPS, CA 15-3 and CEA were determined in metastatic breast cancer patients during treatment. After six months of follow-up the patients were divided into four groups according to the UICC criteria for treatment response. Forty-six patients with a more favorable prognosis (complete remission, partial remission or stable disease) were followed for an extended period. In 30 of the 46 patients at least one marker had increased at the end of the six-month period by at least 25% (TPS in 54%, CA 15-3 in 20%, CEA in 20%). All these 30 patients subsequently developed progression. The prognostic sensitivity was 83%, 30% and 30%, respectively, for TPS, CA 15-3 and CEA. The combination of TPS and CA 15-3 showed a sensitivity of 96%. The median lead time was about 8 months for TPS and CA 15-3, but less than 50% of the patients showed a lead time for CA 15-3 as compared to TPS. We conclude that TPS and CA 15-3 determinations are helpful for the prediction of progression during the follow-up of breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document